LYRA 股价走势图
LYRA 股票价格预测
Lyra Therapeutics Inc
$0
0%
$0
收盘价：May 12, 16:00:00 GMT-4
$0
0%
$0
盘后：May 12, 20:00:00 GMT-4
返回
Lyra Therapeutics Inc (LYRA) 股票价格预测
关键数据
前收盘价
--
开盘价
--
当日区间
-
52周范围
-
交易量
--
平均成交量
--
股息收益率
--
每股收益（TTM）
--
市值
--
什么是 LYRA？
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
